3 results
Primary ObjectiveTo evaluate the efficacy of lumacaftor/ivacaftor combination therapy (LUM/IVA) in subjects with cystic fibrosis (CF) 12 years of age and older who have at least one A455E mutation.Other Objectives* To explore the association between…
Primary:• To evaluate the safety of ORGN001 (formerly ALXN1101) over the first 6 months of treatmentSecondary:• To characterize the pharmacokinetics (PK) of increasing doses of ORGN001 (formerly ALXN1101) • To evaluate the effect of ORGN001 (…
Primary objective• To explore the feasibility of multiple dose administration of oxybutynin via the MedRing OAB system in an outpatient setting.• Safety and tolerability of 28 days of intravaginal dosing of oxybutynin via the MedRingSecondary…